Necrosis News and Research

RSS

Biosimilars show promise for children with IBD, but more research needed

Children with inflammatory bowel disease (IBD) who are doing well on specific biological medications should not be switched to recently approved "biosimilar" products, concludes an expert consensus statement of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.

14 Jul 2015

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Results published today in The New England Journal of Medicine from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared psoriasis or minimal psoriasis at week 16, the study's primary endpoint.

9 Jul 2015

dlDNA marks progression of HBV-related liver disease

The level of serum duplex-linear DNA increases markedly with liver disease progression and development of hepatocellular carcinoma in patients with chronic hepatitis B virus (HBV) infection, suggests research published in Gut.

30 Jun 2015

Statins benefit patients undergoing major lung resection, lower major complications

Statins have been shown to reduce complications from cardiovascular surgery. To determine whether statins might also help those undergoing major lung surgeries, a team at Memorial Sloan Kettering Cancer Center conducted a well-designed study that randomized patients to receive either a statin or placebo before and after surgery.

23 Jun 2015

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Mesothelioma.us, an educational and authoritative website that offers free and in-depth resources for mesothelioma patients and their families, has just released a new case study that focuses on the experimental treatments for the disease.

15 Jun 2015

Study shows that TNFi dose reduction strategy can help in optimal management of RA

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis (RA) patients, a good clinical response to maintenance treatment with a tumour necrosis factor inhibitor (TNFi) was maintained even when the dose was reduced by one-third.

15 Jun 2015

Study opens door to deeper understanding of genetic, molecular aspects underlying sleep disorders

Washington State University Spokane scientists have grown a tiny group of brain cells that can be induced to fall asleep, wake up and even show rebound sleep after "staying up late."

10 Jun 2015

Global RA treatment market expected to increase just over $19 billion by 2020

Analysis from business intelligence provider GBI Research - Rheumatoid Arthritis Market to 2020 - says that the global Rheumatoid Arthritis (RA) treatment market is expected to increase in value, from $14.3 billion in 2013 to just over $19 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 4.1%.

8 Jun 2015

Childhood trauma increases vulnerability to different health problems in later life

Long-term changes in immune function caused by childhood trauma could explain increased vulnerability to a range of health problems in later life, according to new research by the Institute of Psychiatry, Psychology & Neuroscience at King's College London and the NIHR Maudsley BRC.

3 Jun 2015

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

Stempeutics Research, a group company of Manipal Education & Medical Group and a joint venture with Cipla Group, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation for its drug Stempeucel® for the treatment of Thromboangiitis Obliterans.

2 Jun 2015

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Despite surgical advances, pancreatic cancer continues to be one of the most deadly and difficult cancers to manage due to a lack of effective therapies. However, VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) scientists in the lab of Paul B. Fisher, M.Ph., Ph.D., are hoping to change that with a novel combination of an experimental drug and a common antibiotic that has shown promising results in preclinical experiments.

2 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

Study indicates that arthritis patients may not be taking medication as regularly as prescribed

Researchers from the Arthritis Research UK Centre for Epidemiology at The University of Manchester found that 40% of patients scored low on an adherence questionnaire at least once during their time in a recent study, indicating that they might not be taking their expensive biological therapies as regularly as prescribed.

26 May 2015

Researchers explore how low-level electrical stimulation reduces inflammation

The Feinstein Institute for Medical Research, the research arm of the North Shore-LIJ Health System, and SetPoint Medical Inc., a biomedical technology company, today released the results of research on the therapeutic potential of vagus nerve stimulation. In a paper published by Bioelectronic Medicine, Kevin J. Tracey, MD, and his colleagues at the Feinstein Institute, explore how low-level electrical stimulation interacts with the body's nerves to reduce inflammation, a fundamental goal of bioelectronic medicine.

15 May 2015

Study finds link between PTSD and accelerated aging

In recent years, public health concerns about post-traumatic stress disorder (PTSD) have risen significantly, driven in part by affected military veterans returning from conflicts in the Middle East and elsewhere. PTSD is associated with number of psychological maladies, among them chronic depression, anger, insomnia, eating disorders and substance abuse.

10 May 2015

Scientists reveal how breast milk prevents necrotizing enterocolitis in premature babies

The immune-boosting properties of breast milk have long been known. Now a team of scientists led by Johns Hopkins pediatric surgeon-in-chief David Hackam, M.D., Ph.D., says experiments in mice reveal how breast milk works to ward off the development of necrotizing enterocolitis (NEC), a devastating intestinal disorder that affects 12 percent of premature babies and claims the lives of one in four of those who have it.

23 Apr 2015

Tumor necrosis factor helps regulate sensitivity to bitter taste

New research from the Monell Center reveals that tumor necrosis factor (TNF), an immune system regulatory protein that promotes inflammation, also helps regulate sensitivity to bitter taste. The finding may provide a mechanism to explain the taste system abnormalities and decreased food intake that can be associated with infections, autoimmune disorders, and chronic inflammatory diseases.

22 Apr 2015

University of York scientists use low temperature plasmas to treat prostate cancer

Scientists at the University of York have discovered a potential new treatment for prostate cancer using low temperature plasmas (LTPs).

9 Apr 2015

Combination of signaling molecules can inhibit growth of breast cancer cells

Researchers at UT Southwestern Medical Center have uncovered how the body's inflammatory response can alter how estrogen promotes the growth of breast cancer cells.

6 Apr 2015

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets.

1 Mar 2015